Actelion announces share buyback program - up to 10 million shares over a maximum of three years through the first trading line for reactive servicing of employee share ownership schemes
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion announces share buyback program - up to 10 million shares over a
maximum of three years through the first trading line for reactive servicing of
employee share ownership schemes
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL, SWITZERLAND - 5 December 2013 - The Board of Directors of Actelion
Ltd. (SIX: ATLN) has approved a new program to buy back up to 8.31% (up to 10
million shares) of the currently outstanding share capital over the next three
years. The repurchased registered shares will be used for the reactive servicing
of existing employee option and share ownership programs. This will compensate
for a possible dilution of earnings per share as a result of the share ownership
schemes.
At the closing price on 4 December 2013, the maximum buyback volume amounts to
CHF 720 million. The program will start on 9 December 2013, will last until 8
December 2016 at the latest and will be handled through the normal trading line
on the SIX Swiss Exchange.
UBS AG has been commissioned to repurchase the shares. The terms of the buyback
program will be published on 6 December 2013 in the daily press and on the
company's website (www.actelion.com).
###
NOTES TO THE EDITOR
Actelion Ltd
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion first drug Tracleer® (bosentan), an
orally available dual endothelin receptor antagonist, has been approved as a
therapy for pulmonary arterial hypertension. Actelion markets Tracleer through
its own subsidiaries in key markets worldwide, including the United States
(based in South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,300 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI®).
For further information please contact:
Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment
and research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
Press Release PDF:
http://hugin.info/131801/R/1747890/588611.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via GlobeNewswire
[HUG#1747890]
Unternehmensinformation / Kurzprofil:
Datum: 05.12.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 322672
Anzahl Zeichen: 5173
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 135 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion announces share buyback program - up to 10 million shares over a maximum of three years through the first trading line for reactive servicing of employee share ownership schemes"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
